631 results on '"Forst, T"'
Search Results
2. Therapie postprandialer Blutzuckerspitzen – sinnvoll oder nur Blutzuckerkosmetik?: Pro
3. Kardiovaskuläre Aspekte der Diabetestherapie: Endlich Grund zur Freude für Kardiologen
4. Kardiovaskuläre Effekte von Metformin, Sulfonylharnstoffen und Gliniden
5. Investigation of insulin resistance in narcoleptic patients: dependent or independent of body mass index?
6. CEBRANOPADOL, A NOVEL FIRST-INCLASS ANALGESIC: EFFICACY, SAFETY, TOLERABILITY IN PATIENTS WITH PAIN DUE TO DIABETIC PERIPHERAL NEUROPATHY (DPN): WIP16–0478
7. Early fasting glucose measurements can predict later glycaemic response to once weekly dulaglutide
8. Effects of insulin glargine versus metformin on glycemic variability, microvascular and beta-cell function in early type 2 diabetes
9. Insulintherapie bei Patienten mit Herzerkrankungen: Pro und Kontra
10. Pleiotrophic and anti-inflammatory effects of pioglitazone precede the metabolic activity in type 2 diabetic patients with coronary artery disease
11. Dose-finding results in an adaptive, seamless, randomized trial of once-weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD-5)
12. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone
13. A Diabetes Outcome and Progression Trial – Die ADOPT Studie: Mögliche Auswirkungen auf die praktische Therapie des Typ-2-Diabetes mellitus
14. Evidenzbasierte Medizin: Theoretische Grundlagen und aktueller Missbrauch zur Kosteneinsparung im Gesundheitswesen
15. Therapie der diabetischen Polyneuropathie
16. Folgen des Wechselns von zweimal täglich verabreichtem Basalinsulin auf einmal täglich Insulin glargin 300 E / ml (Gla-300) bei Patienten mit Typ-1-Diabetes: Die Phase-4-Studie OPTIMIZE
17. Differential effects of vildagliptin and glimepiride on glucose fluctuations in patients with type 2 diabetes mellitus assessed using continuous glucose monitoring
18. Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin
19. Effect of vildagliptin compared to glimepiride on postprandial proinsulin processing in the β cell of patients with type 2 diabetes mellitus
20. The influence of local capsaicin treatment on small nerve fibre function and neurovascular control in symptomatic diabetic neuropathy
21. Response Letter to D. Singh-Franco et al.
22. Addition of liraglutide in patients with Type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function
23. The effect of human proinsulin C-peptide on erythrocyte deformability in patients with Type I diabetes mellitus
24. The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus
25. Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes
26. Adding insulin glargine vs. NPH insulin to metformin results in a more efficient postprandial β-cell protection in individuals with type 2 diabetes
27. Is there an ectopic secretion of monomeric calcitonin in the human being?
28. Intensification with prandial insulin
29. Successful switch from insulin therapy to treatment with pioglitazone in type 2 diabetes patients with residual β-cell function: results from the PioSwitch Study
30. Differentiation of adipocyte-derived adult mesenchymal stem cells into insulin expressing cells in vitro: OP72
31. The IRIS III study: pioglitazone improves metabolic control and blood pressure in patients with type 2 diabetes without increasing body weight
32. Performance of the continuous glucose monitoring system (CGMS) during development of ketosis in patients on insulin pump therapy
33. Anti-Inflammatory Power of Pioglitazone, Simvastatin and Their Combination in Non-Diabetic High Cardiovascular Risk Patients with Elevated hs CRP: 433-P
34. Association between “diabetic thick skin syndrome” and neurological disorders in diabetes mellitus
35. IRIS II study: the IRIS II score—assessment of a new clinical algorithm for the classification of insulin resistance in patients with Type 2 diabetes
36. The influence of isolated small nerve fibre dysfunction on microvascular control in patients with diabetes mellitus
37. Improved Diagnostic Methods in the Follow-Up of Medullary Thyroid Carcinoma by Highly Specific Calcitonin Measurements*
38. Selbsttitration mit Insulin glargin 300 oder 100 E/ml führt zu verbesserter Wirksamkeit vs. arztgeführter Titration: Vergleich der Studien TAKE-CONTROL, AT.LANTUS und ATLAS bei Menschen mit Typ-2-Diabetes (T2DM)
39. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
40. Comment on: Haider DG, Schaller G, Kapiotis S, Maier C, Luger A, Wolzt M (2006) The release of the adipocytokine visfatin is regulated by glucose and insulin. Diabetologia 49:1909–1914
41. Sequentielle Therapieeskalation mit Dapagliflozin und Saxagliptin verbessert die Insulinsekretion und den Glukagon-Insulin Quotienten im hyperglykämischen Clamp bei Patienten mit einem Diabetes mellitus Typ 2
42. Protein intake and urinary albumin excretion rates in the EURODIAB IDDM Complications Study
43. Repeatability of three-day dietary records in the EURODIAB IDDM Complications Study
44. Dulaglutid: GLP-1-Rezeptoragonist zur einmal wöchentlichen Therapie des Typ-2-Diabetes
45. Glukoseselbstmessung – technische Möglichkeiten und Limitationen
46. Dulaglutid: GLP-1-Rezeptoragonist zur einmal wöchentlichen Therapie des Typ-2-Diabetes
47. Dapagliflozin senkt den postprandialen Blutzucker ohne Anstieg von C-Peptid oder Insulin
48. Response letter to d. Singh-franco et Al
49. Intima Media Dicke - Geeigneter Biomarker für das Therapiemonitoring
50. Early fasting glucose measurements can predict later glycaemic response to once weekly dulaglutide
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.